OASM Oasmia Pharmaceutical AB

Oasmia expands the Management Team

Oasmia expands the Management Team

Oasmia Pharmaceutical AB (NASDAQ: OASM) expands the Management Team in order to directly involve the whole organization in the commercialization of Apealea and other product candidates.

Earlier the Management Team was formed only by the CEO, the CFO and the Executive Chairman.

The following persons are now part of the Management Team.

Mikael Asp, CEO

Anette Sjödin, Chief Business Officer (CBO) and deputy CEO

Joakim Lindén, acting CFO

Sven Rohmann, acting Chief Medical Officer (CMO) (also Member of the Board)

Nina Heldring, Head of Clinical Development

Maria Nilsson Hagberg, Head of Regulatory Affairs

Dzianis Babrou, Head of Research and Development

Elin Trampe, Head of Supply Chain

Richard Herrmann, Strategic Marketing Director

”With this Management Team, Oasmia gets direct access to all necessary competences enabling a successful commercialization of its products. Furthermore, this set up ensures a qualified, fast and transparent decision making as well as immediate implementation since more department heads now are parts of the process”, says Mikael Asp, CEO of Oasmia.

For more information:

Mikael Asp, CEO

Tel:

E-mail:

For further information, email:

Note to editors:

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

Information is also available at -frankfurt.de twitter.com/oasmia

This information was submitted for publication, through the agency of the contact person set out above, at 08:00 PM CET on 10 April 2019.

Attachment

EN
10/04/2019

Underlying

OASMOasmia Pharmaceutical AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oasmia Pharmaceutical AB

Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Vivesto - Termination of coverage

Edison Investment Research is terminating coverage on Vivesto (VIVE), Diurnal Group (DNL), Palace Capital (PCA), Primary Health Properties (PHP), Silver One Resources (SVE), Induction Healthcare (INHC) and Axiom European Financial Debt (AXI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

OASM OASMIA PHARMACEUTICAL AB
02/01/23 February 1, 2023 1 EN
Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Vivesto - Turnaround strategy beginning to deliver

Vivesto capped off its 18-month strategic turnaround with reduced Q1 losses and a stated focus on its ‘string of pearls’ strategy to build its oncology pipeline through in-licensing and M&A. In March, it successfully completed a rights issue, generating net proceeds of SEK134.6m, extending its runway into 2024. This is sufficient to cover a number of clinical and commercial inflection points and execute its strategy. Key upcoming catalysts include the planned 2022 UK and German launches of Apeal...

OASM OASMIA PHARMACEUTICAL AB
06/27/22 June 27, 2022 1 EN
Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Oasmia Pharmaceutical - Delivering on promises

FY21 results highlight delivery on key elements of Oasmia’s ongoing transformation. Notably, ‘rightsizing’ the business and prudent cost control has brought the underlying cash burn rate down to c SEK10m per month in 2021. With the fully secured rights issue expected to raise gross proceeds of c SEK150m, management has guided it can fund operations for 18–24 months. We anticipate material progression can be made across the pipeline during this time, with clinical progress expected from Cantrixil...

OASM OASMIA PHARMACEUTICAL AB
02/25/22 February 25, 2022 1 EN
Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Oasmia Pharmaceutical - Rights issues secured and planned for Q122

Oasmia has announced it has secured a preferential, one-for-five rights issue that will raise gross proceeds of c SEK151m and should alleviate near-term funding requirements. The company’s largest shareholder has agreed to subscribe to its allotment (24.8%) and a consortium of external investors has guaranteed the remainder (75.2%), albeit on a 6.5% cash compensation basis. Subscription rights can be traded from 8 to 17 March. Oasmia has also announced plans to change its name to Vivesto; both t...

OASM OASMIA PHARMACEUTICAL AB
01/20/22 January 20, 2022 1 EN
Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Oasmia Pharmaceutical - Rights issues secured and planned for Q122

Oasmia has announced it has secured a preferential, one-for-five rights issue that will raise gross proceeds of c SEK151m and should alleviate near-term funding requirements. The company’s largest shareholder has agreed to subscribe to its allotment (24.8%) and a consortium of external investors has guaranteed the remainder (75.2%), albeit on a 6.5% cash compensation basis. Subscription rights can be traded from 8 to 17 March. Oasmia has also announced plans to change its name to Vivesto; both t...

OASM OASMIA PHARMACEUTICAL AB
01/20/22 January 20, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch